B+
Bull case
30%
Probability
Target price
$425.00
Analysis reference price unavailable
Analysis 2026-06-18 · RankAlpha Sentiment Codex
WAT
WatersCNYSE / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$395.00
Analysis reference price unavailable
Analysis 2026-06-18 · RankAlpha Sentiment Codex
B-
Bear case
20%
Probability
Target price
$320.00
Analysis reference price unavailable
Analysis 2026-06-18 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-06-18
Recent news sentiment (30D)
+66.0
Positive
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+58.7
Score
AI commentary
Primary-source evidence is strong and directionally positive, but the thesis change is still moderate rather than dramatic. The stock’s post-earnings tone appears constructive, consistent with the beat-and-raise, yet by the June 17, 2026 anchor much of that reset likely sits in the price already. News flow after the May 5 print is thin, social context is unavailable, and analyst-revision breadth is incomplete, so this remains a cautious execution-monitoring long rather than a fresh high-conviction rerating call.
RankAlpha Sentiment Codex - 2026-06-18
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-05-05eventQ1 beat-and-raise reset the FY26 bar higherMedium impact
Waters reported Q1 2026 revenue of $1.267 billion, organic constant-currency growth of 11%, adjusted EPS of $2.70, and raised FY26 guidance to 6.5%-8.0% organic constant-currency growth and $14.40-$14.60 adjusted EPS; that moved the debate from whether the BD assets would dilute growth to whether Waters can sustain the higher bar [#SEC-8K-2026-05-05].
2026-12-31catalystBD biosciences and diagnostics integration is the main multi-quarter upside leverMedium impact
The acquired Biosciences and Diagnostic Solutions businesses contributed $520 million of owned-period Q1 revenue, $40 million above guidance, while Waters said revenue synergies were already showing and embedded $15 million of FY26 organic synergy and $35 million of acquired-business synergy into guidance; sustaining that momentum is central to further upside [#SEC-8K-2026-05-05].
2026-12-31catalystExecution must outrun leverage, amortization, and China frictionMedium impact
The 10-Q shows goodwill rising to about $9.3 billion after the acquisition and total debt at about $5.215 billion as of April 4, 2026, while the 10-K and 10-Q continue to flag China procurement, tariff, and competitive risks; that leaves the stock dependent on durable organic instruments/consumables/service demand rather than a one-quarter spike [#SEC-10Q-2026-05-12][#10-K-2026-02-23].
Recommendation
N/A
No formal recommendation provided.
As of 2026-06-18 • Updated nightlySource: Internal modelMethodology